Abstract
Production of biopharmaceuticals in transgenic plants would involve the creation of a new industry. Those transgenic plants, including staple food crops, could provide many benefits to people all over the world. However, the new industry might require a strict regulation system. It is probable that such a strict system would not be acceptable to Japan or to most developing countries. Many countries should use non-food crops for production of biopharmaceuticals and take on more simple systems. The new industry must develop strategies for promoting the benefits of transgenic plant-derived biopharmaceuticals on both the domestic and worldwide scales.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Monoclonal / biosynthesis
-
Antibodies, Monoclonal / isolation & purification
-
DNA, Recombinant / genetics
-
Drug Contamination / prevention & control
-
Drug Design
-
Genetic Engineering
-
Humans
-
Pharmaceutical Preparations / isolation & purification*
-
Plants, Genetically Modified* / chemistry
-
Protein Processing, Post-Translational
-
Recombinant Fusion Proteins / biosynthesis
-
Recombinant Fusion Proteins / isolation & purification
-
Safety
-
Technology, Pharmaceutical / methods*
Substances
-
Antibodies, Monoclonal
-
DNA, Recombinant
-
Pharmaceutical Preparations
-
Recombinant Fusion Proteins